Please assess the completion status of the following clinical trial:

Trial Title: Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has a diagnosis of primary Type I or II achalasia.~* Patient has no contraindications to the performance of the baseline and postdose HRIM procedures per Investigator discretion.~Key Exclusion Criteria:~* Patient has had any prior esophageal, periesophageal, or gastric surgery, or treatment with sclerosing agent.~* More than 1 pneumatic dilation procedure to a diameter of \> 2 cm in their lifetime.~* Pneumatic dilation procedure to a diameter of \> 2 cm within 1 year prior to randomization. Prior bougie dilation(s) or pneumatic dilation(s) ≤ 2 cm are allowed.~* Prior esophageal injection of botulinum toxin (Botox) within 6 months prior to randomization or more than 2 esophageal Botox injection procedures in their lifetime.~* Patients with malignant or premalignant esophageal lesions.~* Patient has taken any drug that can affect gastrointestinal (GI) motility in the 72 hours before check-in through discharge from the clinic.~Other inclusion and exclusion criteria specified in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IW-1701 (Type: EXPERIMENTAL): Single 5-mg dose of IW-1701 administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).